Both stocks run through our valuation models. Here is how Bioxyne (BXN) and Nestle S.A. (NESN) compare, as of Aug 26, 2026.
As of Aug 26, 2026, Fair Value Calculator sees Nestle S.A. as the less overvalued of the two: Bioxyne trades at A$0.93 versus a fair value of A$0.35 (-63%), while Nestle S.A. trades at CHF 79.82 versus CHF 57.26 (-28%).
Bioxyne
BXN.AU · AUD · Health Care
-63%
upside to fair value
overvalued
PriceA$0.93
Fair ValueA$0.35
Quality65/100
Nestle S.A.
NESN.SW · CHF · Consumer Staples
-28%
upside to fair value
overvalued
PriceCHF 79.82
Fair ValueCHF 57.26
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
BioxyneNestle S.A.
Valuation
23.3×P/E (TTM)23.9×
3.19×P/S (TTM)2.99×
13.11×P/B8.18×
14.3×EV/EBITDA18.5×
2.67×PEG2.31×
—Dividend yield3.9%
—Dividend per shareCHF 3.10
Profitability
19%Net margin10%
32%Operating margin15%
66%Return on equity27%
25%Return on assets7%
Growth
150%Revenue growth (YoY)-2%
—Avg. growth/yr (3Y)-1.9%
68.2%Avg. growth/yr (5Y)1.1%
Balance & size
0.02×Debt / equity1.34×
$153MMarket cap$268B
mixedGrowth qualityweak
Bioxyne leads: 9 to 3 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Bioxyneof which business quality 65 · market factors 75Nestle S.A.of which business quality 64 · market factors 62
ProfitabilityMargins and returns on capital today
92
60
Quality GrowthAre margins and returns improving?
82
43
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
34
94
Low VolatilityCalm price path (market factor)
44
92
MomentumPrice trend over the last 3–12 months (market factor)
88
45
52W MomentumDistance to the 52-week high (market factor)
89
56
Net IssuanceBuybacks instead of dilution
0
94
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Bioxyne
DCF ModelsA$0.49
Earnings-BasedA$0.75
MultiplesA$0.39
Asset-BasedA$0.03
Growth DCFA$0.41
Economic ProfitA$0.22
Growth EarningsA$0.99
22 of 24 models see the stock below the current price.
Nestle S.A.
DCF ModelsCHF 47.70
Earnings-BasedCHF 33.53
Dividend DiscountCHF 34.87
MultiplesCHF 66.73
Asset-BasedCHF 8.55
Growth DCFCHF 45.56
Economic ProfitCHF 32.75
Growth EarningsCHF 55.79
24 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Bioxyne
Bear A$0.24Fair Value A$0.35Bull A$0.43
A$0.93 = current price (white tick)
Nestle S.A.
Bear CHF 35.23Fair Value CHF 57.26Bull CHF 81.98
CHF 79.82 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Bioxyne · Health Care
Quality score65 · Top 25%
Fair value upside-63% · below median
Nestle S.A. · Consumer Staples
Quality score69 · Top 25%
Fair value upside-28% · below median
Bottom line
As of Aug 26, 2026, Fair Value Calculator sees Nestle S.A. as the less overvalued of the two: Bioxyne trades at A$0.93 versus a fair value of A$0.35 (-63%), while Nestle S.A. trades at CHF 79.82 versus CHF 57.26 (-28%).
Nestle S.A. has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.
